Atherosclerosis is a leading cause of death worldwide and is characterized by
lipid-laden foam cell formation. Recently,
pycnogenol (PYC) has drawn much attention because of its prominent effect on
cardiovascular disease (CVD). However, its protective effect against
atherosclerosis and the underlying mechanism remains undefined. Here PYC treatment reduced areas of plaque and
lipid deposition in atherosclerotic mice, concomitant with decreases in total
cholesterol and
triglyceride levels and increases in
HDL cholesterol levels, indicating a potential antiatherosclerotic effect of PYC through the regulation of
lipid levels. Additionally, PYC preconditioning markedly decreased foam cell formation and
lipid accumulation in
lipopolysaccharide (LPS)-stimulated human THP-1 monocytes. A mechanistic analysis indicated that PYC decreased the
lipid-related
protein expression of
adipose differentiation-related protein (ADRP) and
adipocyte lipid-binding protein (ALBP/aP2) in a dose-dependent manner. Further analysis confirmed that PYC attenuated LPS-induced lipid droplet formation via ADRP and ALBP expression through the
Toll-like receptor 4 (TLR4) and nuclear factor-κB (NF-κB) pathway, because pretreatment with anti-TLR4 antibody or a specific inhibitor of NF-κB (
PDTC) strikingly mitigated the LPS-induced increase in ADRP and ALBP. Together, our results provide insight into the ability of PYC to attenuate
bacterial infection-triggered
pathological processes associated with
atherosclerosis. Thus PYC may be a potential lead compound for the future development of antiatherosclerotic CVD
therapy.